Charles Schwab Investment Management Inc. Sells 45,031 Shares of DaVita Inc. (NYSE:DVA)

Charles Schwab Investment Management Inc. lowered its stake in DaVita Inc. (NYSE:DVA) by 8.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 501,601 shares of the company’s stock after selling 45,031 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.61% of DaVita worth $82,227,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Transcendent Capital Group LLC purchased a new position in shares of DaVita in the 3rd quarter worth $25,000. Blue Trust Inc. boosted its position in DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the last quarter. Family Firm Inc. bought a new stake in shares of DaVita during the 2nd quarter valued at about $43,000. Versant Capital Management Inc increased its position in shares of DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after purchasing an additional 155 shares during the last quarter. Finally, Friedenthal Financial bought a new position in shares of DaVita in the 2nd quarter worth approximately $48,000. Institutional investors own 90.12% of the company’s stock.

Insider Activity

In related news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Truist Financial upped their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. UBS Group lifted their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, Bank of America boosted their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Trading Down 1.3 %

Shares of DVA stock opened at $165.71 on Thursday. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The stock has a fifty day simple moving average of $158.42 and a two-hundred day simple moving average of $148.87. The firm has a market capitalization of $13.59 billion, a PE ratio of 18.02, a PEG ratio of 0.94 and a beta of 0.89. DaVita Inc. has a 52-week low of $98.26 and a 52-week high of $169.51.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter in the prior year, the business posted $2.85 EPS. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, analysts predict that DaVita Inc. will post 9.71 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.